Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.77 |
| ▸ | KIT | P10721 | 2/20 | 0.77 |
| ▸ | RAF1 | P04049 | 1/20 | 0.77 |
| ▸ | LCK | P06239 | 1/20 | 0.77 |
| ▸ | RET | P07949 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.77 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3363327 | 0.94 | KDR (0.79) | KDRKITRAF1LCKRET | |
| SCHEMBL3359832 | 0.93 | KDR (0.79) | KDRKITRAF1LCKRET | |
| SCHEMBL3361221 | 0.92 | KDR (0.75) | KDRKITRAF1LCKRET | |
| SCHEMBL3359202 | 0.92 | KDR (0.77) | KDRKITRAF1LCKRET | |
| SCHEMBL13846236 | 0.91 | KDR (0.76) | KDRKITRAF1LCKRET | |
| SCHEMBL20805543 | 0.91 | KDR (0.78) | KDRKITRAF1LCKRET | |
| SCHEMBL3362720 | 0.90 | KDR (0.79) | KDRKITRAF1LCKRET | |
| SCHEMBL3364485 | 0.87 | KDR (0.81) | KDRKITRAF1LCKRET | |
| Osi-930 SCHEMBL633719 | 0.87 | KDR (1.00) | KDRKITRAF1LCKRET | |
| Osi-930 SCHEMBL29352171 | 0.87 | KDR (1.00) | KDRKITRAF1LCKRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010088000-A2 | ANTIFIBROTIC COMPOUNDS AND USES THEREOF | ANGION BIOMEDICA CORP. (US) | 2010-08-05 | — | — | WO | claimed |
| WO-2010088000-A2 | ANTIFIBROTIC COMPOUNDS AND USES THEREOF | ANGION BIOMEDICA CORP. (US) | 2010-08-05 | — | — | WO | disclosed |
| US-7696225-B2 | (2-carboxamido)(3-Amino) thiophene compounds | OSI PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696225-B2 | (2-carboxamido)(3-Amino) thiophene compounds | OSI PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| WO-2009152340-A2 | 2,3-SUBSTITUTED THIOPHENES IN LUNG INFLAMMATION THERAPIES | OSI PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009073139-A2 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN INHIBITOR OF C-KIT | OSI PHARMACEUTICALS, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| US-20090136517-A1 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN INHIBITOR OF C-KIT | OSI PHARMACEUTICALS, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090136517-A1 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN INHIBITOR OF C-KIT | OSI PHARMACEUTICALS, INC. | 2009-05-28 | — | — | US | disclosed |
| EP-1807419-B1 | (2-CARBOXAMIDO)(3-AMINO) THIOPHENE COMPOUNDS | OSI PHARM INC (US) | 2009-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136517-A1 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN INHIBITOR OF C-KIT | KIT, EGFR, AURKC | KDR 57/4885KIT 1/4885RAF1 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.